CASPASE POLYPEPTIDES HAVING MODIFIED ACTIVITY AND USES THEREOF
The technology relates in part to compositions comprising modified caspase-9 polypeptides, compositions comprising nucleic acids coding for modified caspase-9 polypeptides, chimeric modified caspase-9 polypeptides, and methods of use thereof, including methods for cell therapy. Methods for cell therapy include modifying transfused cells to express an inducible modified caspase-9 protein, with reduced basal activity in the absence of the inducer.
1 . A method for controlling the survival of therapeutic cells in a subject, comprising administering to a subject in need thereof
a) modified cells comprising a promoter operably linked to a polynucleotide that encodes a chimeric polypeptide comprising
i. a multimerization region and
ii. a modified caspase-9 polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and comprises at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, and A331K; and
b) an amount of a multimeric ligand that binds to the multimerization region effective to reduce the number of cells administered in (a).
2 . The method of claim 1 , wherein the modified caspase-9 polypeptide further comprises at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, N405Q (codon optimized), D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, A331K, T317S, S144A, S144D, N405Q, 402 GCFNF 406 ISAQT (Casp-10) (SEQ ID NOS 224 and 225), F404Y, D330A, T317A, S183A, S195A, S196A, F404T, F404W, N405F, F406T, D315A, A316G, F319W, Y153A, Y153F, and S307A.
3 . The method of claim 1 , wherein the cell further comprises a polynucleotide that encodes a heterologous polypeptide selected from the group consisting of chimeric antigen receptor, T cell receptor, and T cell receptor-based chimeric antigen receptor.
4 . The method of claim 3 , wherein the promoter is operably linked to the polynucleotide that encodes the chimeric polypeptide and the polynucleotide that encodes the heterologous polypeptide.
5 . The method of claim 4 , wherein the nucleic acid further comprises a polynucleotide encoding a linker polypeptide between the polynucleotide that encodes the chimeric polypeptide and the polynucleotide that encodes the heterologous polypeptide, wherein the linker polypeptide separates the translation products of the first and second polynucleotides during or after translation.
6 . The method of claim 1 , wherein the multimerization region comprises an FKBP12 region.
7 . The method of claim 6 , wherein the ligand is AP1903.
8 . The method of claim 1 , wherein the cell is a human cell.
9 . The method of claim 1 , wherein the number of therapeutic cells is reduced by about 50% following administration of the multimeric ligand.
10 . The method of claim 1 , wherein the therapeutic cells are selected from the group consisting of T cells, tumor infiltrating lymphocytes, NK-T cells, CAR-expressing cells, TCR-expressing cells, and NK cells, further comprising detecting the presence of graft versus host disease or cytokine release syndrome in the subject after administering the therapeutic cells to the subject, and before administering the multimeric ligand.
11 . The method of claim 10 , wherein after administration of the multimeric ligand, the number of therapeutic cells causing graft versus host disease or cytokine release syndrome in the subject cells is reduced.
12 . A nucleic acid comprising a promoter operably linked to a polynucleotide that encodes a chimeric polypeptide, wherein the chimeric polypeptide comprises: a multimerization region and a modified caspase-9 polypeptide comprising
an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and
at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, and A331K.
13 . A nucleic acid comprising a promoter operably linked to
a) a first polynucleotide that encodes a chimeric polypeptide, wherein the chimeric polypeptide comprises: a multimerization region and a modified caspase-9 polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and
at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, and A331K; and
b) a second polynucleotide that encodes a heterologous polypeptide selected from the group consisting of chimeric antigen receptor, T cell receptor, and T cell receptor-based chimeric antigen receptor.
14 . A nucleic acid comprising a promoter operably linked to
a) a first polynucleotide that encodes a chimeric polypeptide, wherein the chimeric polypeptide comprises: a multimerization region and a modified caspase-9 polypeptide comprising
an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and
at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, N405Q (codon optimized), D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, A331K, T317S, S144A, S144D, N405Q, 402 GCFNF 406 ISAQT (Casp-10) (SEQ ID NOS 224 and 225), F404Y, D330A, T317A, S183A, S195A, S196A, F404T, F404W, N405F, F406T, D315A, A316G, F319W, Y153A, Y153F, and S307A; and
b) a second polynucleotide that encodes a heterologous polypeptide selected from the group consisting of chimeric antigen receptor, T cell receptor, and T cell receptor-based chimeric antigen receptor.
15 . The nucleic acid of claim 12 , wherein the modified caspase-9 polypeptide further comprises at least one amino acid substitution selected from the group consisting of S196D, F406A, F406W, F406Y, N405Q (codon optimized), D330E, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316ATPF319AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, A331K, T317S, S144A, S144D, N405Q, 402GCFNF406ISAQT (Casp-10) (SEQ ID NOS 224 and 225), F404Y, D330A, T317A, S183A, S195A, S196A, F404T, F404W, N405F, F406T, D315A, A316G, F319W, Y153A, Y153F, and S307A.
16 . The nucleic acid of claim 14 , wherein the nucleic acid further comprises a polynucleotide encoding a linker polypeptide between the first and second polynucleotides, wherein the linker polypeptide separates the translation products of the first and second polynucleotides during or after translation.
17 . The nucleic acid claim 12 , wherein the multimerization region comprises an FKBP12 region.
18 . A modified cell comprising a nucleic acid of claim 12 .
19 . The cell of claim 18 , wherein the cell is a human cell.
20 . The cell of claim 18 , wherein the cell is a T cell, tumor infiltrating lymphocyte, NK-T cell, TCR-expressing cell, or NK cell.
21 . The cell of claim 18 , wherein the modified cell is an autologous cell.
22 . The cell of claim 18 , wherein the modified cell is an allogeneic cell.
23 . A modified cell comprising a nucleic acid of claim 14 .
24 . The cell of claim 18 , further comprising a nucleic acid that encodes a heterologous polypeptide selected from the group consisting of chimeric antigen receptor, T cell receptor, and T cell receptor-based chimeric antigen receptor.
25 . A modified caspase-9 polypeptide, comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and comprising at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, and A331K.
26 . The modified caspase-9 polypeptide of claim 25 wherein the modified caspase-9 polypeptide further comprises at least one amino acid substitution selected from the group consisting of S196D, F406A, F406W, F406Y, D330E, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, and A331K.
27 . The modified caspase-9 polypeptide of claim 25 , wherein the modified caspase-9 polypeptide further comprises at least one amino acid substitution selected from the group consisting of S196D, F406A, F406W, F406Y, N405Q (codon optimized), D330E, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, A331K, T317S, S144A, S144D, N405Q, 402 GCFNF 406 ISAQT (Casp-10) (SEQ ID NOS 224 and 225), F404Y, D330A, T317A, S183A, S195A, S196A, F404T, F404W, N405F, F406T, D315A, A316G, F319W, Y153A, Y153F, and S307A.
28 . A chimeric polypeptide comprising a multimerization region and a modified caspase-9 polypeptide of claim 25 .
29 . A method of administering transduced or transfected donor T cells to a human subject in need thereof, comprising
a) administering transduced or transfected allogeneic donor T cells to the human subject, wherein:
the donor T cells have been transduced or transfected with a nucleic acid comprising
(i) a promoter region; and
(ii) a polynucleotide that encodes a chimeric protein comprising a multimeric ligand binding region and a modified caspase-9 polypeptide, wherein
(1) the promoter region is operatively linked to the polynucleotide,
(2) the multimeric ligand binding region comprises a FKBP12 polypeptide comprising an amino acid substitution at position 36 selected from the group consisting of valine, isoleucine, leucine, and alanine; and
(3) the modified caspase-9 polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and comprises at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, and A331K; and
b) administering a multimeric ligand that binds to the multimeric binding region to the subject.
30 . The method of claim 29 , wherein the cells are allogeneic to the subject.
31 . The method of claim 29 , wherein the cells are autologous to the subject.
32 . The method of claim 29 , wherein alloreactive donor T cells are present in the subject following (a).
33 . The method of claim 32 , wherein the number of alloreactive donor T cells is reduced at least 90% within 24 hours following administration of the multimeric ligand.
34 . A method of treating graft versus host disease, comprising administering a multimeric ligand that binds to a multimeric ligand binding region to a human subject who has undergone cell therapy using donor T cells, wherein
a) donor T cells introduced for the therapy express a chimeric protein comprising
(i) the multimeric ligand binding region comprises a FKBP12 polypeptide comprising an amino acid substitution at position 36 selected from the group consisting of valine, isoleucine, leucine, and alanine; and
(ii) a modified caspase-9 polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and comprising at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, and A331K; and
b) following the cell therapy, the subject exhibits graft versus host disease symptoms wherein alloreactive donor T cells are present.
35 . The method of claim 34 , wherein the number of donor T cells is reduced at least 90% within 24 hours following administration of the multimeric ligand.
36 . The method of claim 34 , wherein alloreactive donor T cells are present in the subject and the number of alloreactive donor T cells is reduced at least 90% within 30 minutes following administration of the multimeric ligand.
37 . A method of stem cell transplantation, comprising
a) administering a stem cell transplant to a human subject; and
b) administering a cell of claim 18 to the subject.
38 . A method of administering a multimeric ligand to a human subject who has undergone cell therapy using modified cells that express a chimeric protein, wherein the chimeric protein comprises
(i) a multimeric ligand binding region comprises a FKBP12 polypeptide comprising an amino acid substitution at position 36 selected from the group consisting of valine, isoleucine, leucine, and alanine; and
(ii) a modified caspase-9 polypeptide comprising an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 9, and comprising at least one amino acid substitution selected from the group consisting of D330E, S196D, F406A, F406W, F406Y, D330G, D330N, D330S, D330V, L329E, C403A, C403S, C403T, N405A, 316 ATPF 319 AVPI (SMAC/Diablo) (SEQ ID NOS 226 and 227), T317C, P318A, F319A, N405T, T317E, F326K, D327G, D327K, D327R, Q328K, Q328R, L329G, L329K, and A331K
comprising administering the multimeric ligand to the human subject, wherein the multimeric ligand binds to the multimeric ligand binding region.
39 . The method of claim 38 , wherein the number of modified cells in the subject is reduced at least 50% within 24 hours following administration of the multimeric ligand.
40 . The method of claim 38 , wherein the modified cells are autologous to the subject.
41 . The method of claim 38 , wherein the modified cells are allogeneic to the subject.
42 . The method of claim 38 , wherein the multimeric ligand is AP1903.
43 . The method of claim 38 , wherein the modified cells comprise a nucleic acid that comprises
a) a promoter;
b) a polynucleotide that encodes the chimeric protein; and
c) a polynucleotide that encodes a heterologous polypeptide selected from the group consisting of chimeric antigen receptor, T cell receptor, and T cell receptor-based chimeric antigen receptor.
44 . The method of claim 43 , wherein the promoter is operably linked to the polynucleotide that encodes the chimeric polypeptide and the polynucleotide that encodes the heterologous polypeptide.